Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals, Inc. engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product candidate VP-102, is a proprietary topical therapy used in common skin indications including molluscum contagiosum and verruca vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Verrica Pharmaceuticals reports strong Q3 revenue growth and promising therapies

Verrica Pharmaceuticals' Q3 performance reflects strong revenue generation from YCANTH and promising developments in novel therapies like VP-315.
While facing challenges in market clearance efforts and significant SG&A costs, the company's strategic initiatives position it for future growth.
Opportunities lie in expanding market presence, optimizing costs, and protecting intellectual property to drive profitability and innovation.

Verrica Pharmaceuticals reports robust Q4 earnings and eyes regulatory milestones

Verrica Pharmaceuticals showcased strong financial performance with $1.9 million in YCANTH net revenue and 94% gross margins for 2023.
Strategic partnerships, pipeline advancements, and progress in eliminating market challenges position the company for future growth.
Challenges in sampling activity, revenue forecasting, and regulatory uncertainties require careful navigation for sustained success.
Opportunities in distribution expansion, revenue optimization, and regulatory advancements offer avenues for continued development and success.

Verrica Pharmaceuticals excels in Q1 with strong revenue growth

Verrica Pharmaceuticals demonstrated strong performance in Q1 2024 with significant revenue generation and pipeline advancements.
While facing financial challenges and uncertainties, the company's strategic strengths and opportunities position it well for future growth.
Addressing cost management, market integrity, and maximizing revenue potential will be crucial for sustaining profitability and market leadership.

Verrica Pharmaceuticals excels in Q2, eyes market expansion opportunities

Verrica Pharmaceuticals' Q2 performance reflects strong revenue growth and promising developments in product pipelines. While challenges exist in accelerating demand and maintaining profitability, the company's strategic focus on partnerships and market optimization positions it well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

SAN DIEGO--(BUSINESS WIRE)---- $VRCA #VRCA--Verrica Pharmaceuticals Inc. (VRCA) Received a Complete Response Letter from the FDA relating to its New Drug Application for VP-102

VRCA Investor Update: Robbins LLP Reminds Investors of Class Action Against Verrica Pharmaceuticals Inc. (VRCA)

After losing some value lately, a hammer chart pattern has been formed for Verrica Pharmaceuticals Inc. (VRCA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Here's Why Verrica Pharmaceuticals Inc. (VRCA) Could be Great Choice for a Bottom Fisher

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming August 5, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (NASDAQ: VRCA) securities between May 28, 2021 and May 24, 2022, inclusive (the “Class Period”). If you suffered a loss on your Verrica investments or would like to inquire about potentially pursu

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verrica Pharmaceuticals Inc. (VRCA)

Stockholder Alert: Robbins LLP Informs Investors of Class Action Against Verrica Pharmacuticals Inc. (VRCA)

NEW YORK , June 10, 2022 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: VRCA) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Verrica securities between May 28, 2021 and May 24, 2022, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/vrca.

Bronstein, Gewirtz & Grossman, LLC Notifies Verrica Pharmaceuticals Inc. (VRCA) Investors of Class Action and Encourages Investors to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)---- $VRCA #VRCA--Verrica Pharmaceuticals Inc. (VRCA) Received a Third Complete Response Letter from the FDA relating to its New Drug Application for VP-102

VRCA Stockholder News: Robbins LLP Investigates Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Stockholders

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming August 5, 2022 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (NASDAQ: VRCA) securities between May 28, 2021 and May 24, 2022, inclusive (the “Class Period”). Investors suffering losses on their Verrica investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their le

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verrica Pharmaceuticals Inc. (VRCA)

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) between May 28, 2021 and May 24, 2022, both dates inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than August 5, 2022. SO WHAT: If you purchased Verrica securities during the Class Period you may be entitled to compensation

EQUITY ALERT: Rosen Law Firm Encourages Verrica Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – VRCA

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of Pennsylvania on behalf of those who acquired Verrica Pharmaceuticals, Inc. (“Verrica”) (NASDAQ: VRCA) securities from May 28, 2021 through May 24, 2022, both dates inclusive (the “Class Period”). Investors have until August 5, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Verrica is a dermatology

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Verrica Pharmaceuticals, Inc. (VRCA) Investors

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Verrica Pharmaceuticals, Inc. (“Verrica” or the “Company”) (NASDAQ: VRCA) in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons and entities who purchased or otherwise acquired Verrica securities between May 28, 2021 and May 24, 2022, both dates inclusive (the “Class Period”).

VERRICA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Verrica Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (NASDAQ: VRCA) securities between May 28, 2021 and May 24, 2022, inclusive (the “Class Period”). Verrica investors have until August 5, 2022 to file a lead plaintiff motion. Investors suffering losses on their Verrica investments are encouraged to contact the Law Offices of Howard G. Smi

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Verrica Pharmaceuticals Inc. (VRCA) Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Eastern District of Pennsylvania captioned Gorlamari v. Verrica Pharmaceuticals, Inc., et al., Case No. 22-cv-2226, on behalf of persons and entities that purchased or otherwise acquired Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (NASDAQ: VRCA) securities between May 28, 2021 and May 24, 2022, inclusive (the “Class Pe

VRCA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc. (VRCA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Here's Why Verrica Pharmaceuticals Inc. (VRCA) is Poised for a Turnaround After Losing 70.4% in 4 Weeks

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Verrica Pharmaceuticals, Inc. (“Verrica” or the “Company”) (NASDAQ: VRCA) on behalf of Verrica stockholders. Our investigation concerns whether Verrica has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. Verrica is a dermatology therapeutics company that develo

VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Verrica Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (NASDAQ: VRCA). The investigation concerns whether Verrica has violated the federal securities laws and/or engaged in other unlawful business practices. Verrica is a dermatology therapeutics company that develops and commercializes treatments for people with skin diseases in the United States. On May 24, 2022, after the market closed,

Kirby McInerney LLP Announces an Investigation of Shareholder Claims on Behalf of Verrica Pharmaceuticals Inc. (VRCA) Investors

Verrica Pharmaceuticals' (VRCA) new drug application for VP-102 to treat molluscum contagiosum faces rejection from the FDA for a second time.

Verrica (VRCA) Down 64% as Molluscum Drug Gets CRL From FDA

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (NASDAQ: VRCA) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Verrica investments or would like to inquire about potentially pursuing claims to recover your loss under the federal sec

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Investors

BENSALEM, Pa--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (NASDAQ: VRCA) investors concerning the Company's possible violations of federal securities laws. On May 24, 2022, after the market closed, Verrica announced that the U.S. Food and Drug Administration (“FDA”) had issued a Complete Response Letter regarding its New Drug Application for molluscum contagiosum treatment, VP-102. Specifically

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (NASDAQ: VRCA) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On May 24, 2022, after the market closed, Verrica announced that the U.S. Food and Drug Administration (“FDA”) had issued a Complete Response Letter regarding its N

The Law Offices of Frank R. Cruz Announces Investigation of Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Investors

BlackSky Technology

Enochian Biosciences Inc

Kohl's

Maxar Technologies

Valvoline

A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore and bring order to the markets.

6 Stocks Halted In Wednesday's Session: Here's Why

Verrica Pharmaceuticals Inc (NASDAQ: VRCA) was slapped with a third FDA rejection for YCANTH (VP-102) as general contract manufacturing organization challenges continue to plague the approval. RBC Capital Markets has downgraded the stock to Sector Perform from Outperform.

RBC Capital Slashes Verrica's Price Target After Third Rejection - What's Next?

VRCA stock is sinking over 50% in morning trading after the FDA declined to approve the company's treatment for "a viral skin disease." The post Why Is Verrica Pharmaceuticals (VRCA) Stock Plunging 55% Today?

Why Is Verrica Pharmaceuticals (VRCA) Stock Plunging 55% Today?

Shares of Verrica Pharmaceuticals Inc. VRCA, -11.75% tumbled 54.5% in premarket trading on Wednesday, the day after the company told investors it received a complete response letter from the Food and Drug Administration relating to the application for the company's experimental treatment for molluscum contagiosum, an infection caused by a poxvirus. The letter cited problems with the contract manufacturing organization Sterling Pharmaceuticals Services LLC, which made the bulk solution drug product used in the therapy, VP-102.

Verrica's stock slides after getting second complete response letter from FDA

The FDA has issued a Complete Response Letter (CRL) regarding Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) marketing application for VP-102 for molluscum contagiosum. The only deficiency listed in the CRL was related to the deficiencies identified at a general reinspection.

Why Verrica Pharma Shares Are Plunging Today

Verrica has been advised that PAI (Pre-Approval Inspection) was conducted at Sterling and is not aware of any reported observations related to the PAI of VP-102 operations

Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC

News for Verrica Pharmaceuticals Inc Stock (VRCA)